arrow_back Back to App

Access to Experimental Drugs: Expanding Right to Try

This bill aims to make experimental drugs more accessible for patients with serious illnesses. It allows the use of substances that have completed initial trials, even if they are classified as controlled substances. This gives sick individuals a greater chance at treatment when standard methods fail.
Key points
Expands patients' right to try experimental drugs, including certain controlled substances.
Enables access to drugs that have completed Phase I clinical trials and show promising results.
Offers hope to seriously ill patients for access to innovative therapies previously unavailable.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1825
Sponsor: Rep. Blumenauer, Earl [D-OR-3]
Process start date: 2023-03-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Right to Try Clarification Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1825.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-28.

What are the main provisions?

Key points include:

  • Expands patients' right to try experimental drugs, including certain controlled substances.
  • Enables access to drugs that have completed Phase I clinical trials and show promising results.
  • Offers hope to seriously ill patients for access to innovative therapies previously unavailable.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Blumenauer, Earl [D-OR-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health